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A source of debate in the ﬁeld of health care priority setting is whether health gains should be weighted
differently for different groups of patients. The debate has recently focused on the relative value of life
extensions for patients with short life expectancy. However, few studies have examined empirically
whether society is prepared to fund life-extending end-of-life treatments that would not meet the
reimbursement criteria used for other treatments.
A web-based discrete choice experiment was conducted in 2012 using a sample of 3969 members of
the general public in England and Wales. The study design was informed by the National Institute for
Health and Care Excellence's supplementary policy for the appraisal of life-extending end-of-life treat-
ments. The choice tasks involved asking respondents which of two hypothetical patients they would
prefer to treat, assuming that the health service has enough funds to treat only one of them. Conditional
logit regressions were used for modelling.
Choices about which patient to treat were inﬂuenced more by the sizes of treatment gains than by
patients' life expectancy without treatment. Some respondents appear to support a health-maximisation
type objective throughout, whilst a small minority always seek to treat those who are worse off without
treatment. The majority of respondents, however, seem to advocate a mixture of the two approaches.
Overall, we ﬁnd little evidence that members of the general public prefer to give higher priority to life-
extending end-of-life treatments than to other types of treatment. When asked to make decisions about
the treatment of hypothetical patients with relatively short life expectancies, most people's choices are
driven by the size of the health gains offered by treatment.
© 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Economic evaluation is used to estimate the efﬁciency of health
technologies and subsequently to inform decisions about whether
those technologies should be reimbursed. A common approach is to
measure the health beneﬁts of a given technology in terms of
quality-adjusted life years (QALYs) (Weinstein and Stason, 1977).
The cost-effectiveness of the technology can be expressed as cost
per QALY gained. Decisions about whether to reimburse the tech-
nology can then be guided by comparing the cost-effectiveness ofics, 7th ﬂoor Southside, 105
Ltd. This is an open access article uthat technology to some threshold value that reﬂects displaced
activities (Towse et al., 2002).
If it is assumed that the principal objective of health care is to
maximise population health using available resources (Culyer,
1997) and that the QALY is an acceptable measure of health
beneﬁt, it follows that health care resources should be prioritised so
as to maximise the total number of QALYs gained. This ‘QALY-
maximisation’ rule (Dolan et al., 2005) entails distributive
neutrality e it does not incorporate concerns for how the beneﬁts
are distributed across individuals.
However, maximising health may not be the only purpose:
health care systems may also have other objectives, such as
reducing health inequalities. As well as evaluating the evidence on
cost-effectiveness, agencies carrying out health technology ap-
praisals are often expected to make and apply social value judge-
ments, about what is appropriate and acceptable for society.nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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people value QALYs differently depending on how they are
distributed, the characteristics of the patients receiving them, and
the characteristics of the health effects.
Health care decision makers in a number of countries have been
considering whether and how toweight health gains to account for
equity considerations, such as concern for those whose health
prospects are poorest. In the Netherlands, for example, broad
consensus has been reached to use the principle of ‘proportional
shortfall’ as the basis for equity weighting (van der Wetering et al.,
2013). This involves giving priority to patients who will lose the
greatest proportion of their remaining health expectancy due to
their condition. In England and Wales, the National Institute for
Health and Care Excellence (NICE), the organisation responsible for
producing advice on the use of health technologies in the National
Health Service, has introduced a policy that effectively gives higher
priority to life-extending, ‘end-of-life’ treatments than to other
types of treatments. This constitutes a departure from the In-
stitute's ‘reference case’ position (NICE, 2013) whereby all QALYs
are deemed to be of equal social value, regardless of to whom they
accrue and the context in which they are enjoyed. This paper ex-
amines society's preferences regarding the prioritisation of life-
extending end-of-life treatments. The NICE policy is used as an
example and as the framework for the study design. However, the
issues explored have relevance in all countries seeking to under-
stand the extent of societal support for giving priority to patients
with short life expectancy.Table 1
Attributes and levels used in the study.
Attribute Unit Levels
Life expectancy without treatment Months 3, 12, 24, 36, 60
Quality-of-life without treatment % 50, 100
Life expectancy gain from treatment Months 0, 1, 2, 3, 6, 12
Quality-of-life gain from treatment % 0, 25, 501.1. NICE's end-of-life policy
In January 2009, NICE issued supplementary advice for
appraising life-extending, end-of-life treatments (NICE, 2009a).
This advice constitutes an explicit departure from the reference
case position above. It indicates that if certain criteria are met, it
may be appropriate to recommend the use of treatments for ter-
minal illness that offer an extension to life even if their base case
cost-effectiveness estimates exceed the range normally considered
acceptable (Rawlins and Culyer, 2004).
The current criteria, enshrined in NICE's updated methods guide
(NICE, 2013), are set out below; if met, the Appraisal Committee is
asked to consider the impact of giving greater weight to the
treatment gains achieved in the later stages of disease.
1. The treatment is indicated for patients with short life expec-
tancy (normally less than 24 months).
2. The treatment offers an extension to life compared to current
NHS treatment (normally at least three additional months).
3. The treatment is licensed, or otherwise indicated, for small pa-
tient populations (normally less than 7000 patients).
In response to concerns expressed during the consultation that
there is little evidence to support the premise that society is pre-
pared to fund life-extending end-of-life treatments that would not
meet the cost-effectiveness criteria used for other treatments
(NICE, 2009b), a few studies of people's preferences regarding end-
of-life have been undertaken in the UK (Linley and Hughes, 2013;
Brazier et al., 2013) and elsewhere (Olsen, 2013; Pinto-Prades
et al., 2014). The ﬁndings are mixed, with evidence of support for
an end-of-life premium reported by Brazier et al. (2013) and Pinto
Prades et al. (2014) but not by Linley and Hughes (2013) or Olsen
(2013). Notwithstanding these recent additions to the empirical
literature, the evidence remains limited and there have been calls
for further exploration of the issues (Green, 2011).1.2. Objectives
The primary aim of this study is to investigate the extent to
which the policy of giving higher priority to life-extending end-of-
life treatments (as deﬁned by NICE) than to other types of treat-
ment is consistent with the stated preferences of members of the
general public in England and Wales. Preliminary studies, reported
elsewhere (Shah et al., 2011; 2014), tested the proposed methods
and found weak evidence of public support for giving priority to
end-of-life patients, all else being equal. A further aim is to add to
the growing literature on public preferences regarding the priori-
tisation of health care, which can be used to support an ‘empirical
ethics’ approach to allocating health care resources (Richardson
and McKie, 2005).
2. Methods
2.1. Framework
There are many stated preference techniques that can be used to
elicit public preferences regarding health care priority setting (Ryan
et al., 2001). Health economists typically prefer choice-based
techniques that reﬂect the view that the value of something is
measured by howmuch one is willing to trade or sacriﬁce to obtain
it. One such technique, the discrete choice experiment (DCE), pro-
duces quantitative trade-offs between different factors based on
hypothetical choices (Louviere et al., 2000). DCEs are typically
implemented in surveys comprising several ‘choice sets’, each
containing competing alternative ‘proﬁles’ described using ‘attri-
butes’ and a range of attribute ‘levels’. Respondents are asked to
choose between these alternative proﬁles, and the resulting choices
are analysed to estimate the relative contribution of each of the
attribute levels to overall utility (Lancsar and Louviere, 2008).
DCE data are modelled within a random utility framework,
which assumes the utility (Unj) that respondent n obtains from
choosing alternative j can be separated into an explainable
component (Vnj) and an unexplainable component (εnj):
Unj ¼ Vnj þ εnj
The researcher does not observe εnj and treats it as random.
Assuming that the random terms are independently and identically
distributed extreme value, the conditional logit model can be used
to estimate the probability of alternative i being chosen from the
complete set of alternatives (j ¼ 1, …,J):
Pni ¼
eVni
PJ
j¼1e
Vnj
j ¼ 1;…; J
2.2. Attributes and levels
The selection of attributes and levels (Table 1) was based on
NICE's criteria (above) and informed by the ﬁndings of our pre-
liminary studies (Shah et al., 2011; 2014). ‘Life expectancy without
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for criteria 1 and 2. For life expectancy without treatment, a level
representing the cut-off of 24 months was included, as well as two
levels smaller and two levels larger than this cut-off (three months,
12 months; 36 months, 60 months). Larger levels were considered
but omitted due to concerns about how the lives would be dis-
played visually using the computer-based diagrams. Similarly, the
current ‘life expectancy gain from treatment’ cut-off of three
months was included, as well as two smaller and two larger levels
(one month, two months; six months, 12 months). In addition,
0 months was included in order to examine preferences for end-of-
life treatments that offer no life extension.
The inclusion of quality-of-life attributes was driven by the
ﬁnding in the preliminary studies that many respondents appeared
to favour the prioritisation of quality-of-life-improving treatments
over life-extending treatments (Shah et al., 2011; 2014). We
described this attribute using a health scale ranging from ‘dead’
(0%) and ‘full health’ (100%).
Whilst other studies have presented quality-of-life using a wide
range of levels (Baker et al., 2010a), our piloting work indicated that
this may be challenging for respondents to interpret. We therefore
included only two levels for the ‘quality-of-life without treatment’
attribute: 50% and 100%. The concept of ‘50% health’ was explained
as follows: “Suppose there is a health state which involves some
health problems. If patients tell us that being in this health state for
two years is equally desirable as being in full health for one year,
then we would describe someone in this health state as being in
50% health.” The three levels for the ‘quality-of-life gain from
treatment’ attribute were designed to represent treatments that: (i)
offer no health improvement (0% gain); (ii) restore the patient to
full health (50% gain); and (iii) offer some improvement but do not
restore the patient to full health (25% gain).
Other potential attributes, such as the patient's age, were
considered but eventually omitted from the ﬁnal design in order to
restrict the complexity of the choice tasks. Whilst the literature is
inconclusive with regard to the number of attributes that should be
included in DCEs, some researchers have suggested that when tasks
become too complex respondents may not make trade-offs but
instead adopt other decision heuristics or lexicographic decision
rules (Witt et al., 2009). We therefore chose to focus on the attri-
butes that are most salient to the policy context for NICE.
2.3. Experimental design
A full factorial design using the attributes and levels in Table 1
results in 5*2*6*3 ¼ 180 possible proﬁles, but some combinations
would result in implausible scenarios. The sum of quality-of-life
without treatment and quality-of-life gain from treatment cannot
exceed 100%. We also imposed a constraint that the sum of life
expectancy gain from treatment and quality-of-life gain from
treatment must be greater than zero, or else the treatment would
offer no improvement. Imposing these constraints left 110 proﬁles,
with 5995 possible pairwise choices sets to select from.
Using the STATA software (StataCorp, 2013), 80 pairwise choice
sets were constructed from these 110 proﬁles using a D-optimality
algorithm (Carlsson and Martinsson, 2003) with the attribute co-
efﬁcients set to zero. The design allowed for the estimation of both
main effects and selected interaction effects (see Section 2.7 for
details). All of the choice sets were checked for plausibility, and no
manual alteration of the design was required.
There is little guidance in the literature on the optimal number
of DCE tasks to ask each respondent. The social preference DCE
studies reviewed by Green (2007) used between one and 18 choice
sets per respondent; whilst in a review of 79 conjoint analysis
applications in health, Marshall et al. (2010) report that themajority of studies used between seven and 15 choice sets. We
opted to organise the 80 choice sets into eight blocks of 10 choices.
All 80 choice sets were classiﬁed into one of 13 ‘choice types’ (see
Table 3) which were spread across the blocks. For example, the
experimental design included choice sets in which one proﬁle
could be said to ‘dominate’ the other (choice type 1 in Table 3). We
ensured that all of the blocks contained at least one but no more
than two such choice sets. Apart from this manual distribution of
choice types, the choice sets were assigned to blocks at random.
To control for potential bias due to the positioning of choice
options (Spalek and Hammad, 2005), ‘mirror’ blocks were gener-
ated to match the eight blocks described above. These consisted of
the same 10 choice sets but switched the labels and positions
assigned to the two alternatives e i.e. the alternative ‘patient A’ in
the original block choice set appears in the corresponding mirror
block choice set as ‘patient B’ (and vice versa). Including these
mirror blocks meant that there were a total of 16 different versions
of the survey.2.4. Questionnaire design and scenario presentation
The choice sets were included in a self-completion survey
administered over the Internet. Adapting the design of an existing
survey used in research elsewhere (Brazier et al., 2013), we pre-
sented the attributes levels for two hypothetical patients using a
combination of diagrams and text descriptions (Fig. 1).
The survey began with instructions which introduced the dia-
grams showing how different illnesses and treatments affect peo-
ple's health and life expectancy. Respondents were asked which
patient they thought should be treated, assuming that the health
service has only enough funds to treat one of the two patients, and
that there are no alternative treatments available. It was emphas-
ised that there are no right or wrong answers.
Respondents were advised that they would be given informa-
tion about the patients' health and life expectancy with and
without treatment, but that no other information about the pa-
tients is available (except that they are both adults). To prevent
respondents frommaking choices based on hope that a curemay be
found in the future, they were told that “the nature of the illnesses
is such that further treatment will not be possible if either patient is
not treated today e this is the only opportunity for treatment.”
Although such ‘hope effects’ may exist and inﬂuence people's
choices regarding priority setting, we did not consider them to be
pertinent to this study. The treatments typically considered under
NICE's end-of-life policy tend not to offer life extensions that are
long enough for the realistic possibility of cures being discovered
and made available for use during the intervening period.
No indifference or ‘status quo’ optionwas offered, in accordance
with best practice guidelines (Bridges et al., 2011). The patients,
illnesses and treatments were described in generic terms (e.g.
“patient A's illness”) since the use of labels (e.g. “cancer”) may
induce emotional and biased responses. This is supported by the
ﬁndings of Roberts et al. (1999) who found that the level of
respondent engagement was not sensitive to the provision of
supporting clinical information.
The 10 standard DCE tasks were presented to respondents in a
random order so as to ensure that order bias is not systematic
across the sample. After these, respondents were presented with
two further tasks which sought to examine the impact of intro-
ducing additional information about how long the patients had
known about their illnesses (not reported in this paper).
After completing these tasks, respondents were asked tick-box
questions about their background and health. Finally, they were
invited to leave comments if they so wished.
Fig. 1. Example of diagram and text used in the DCE tasks.
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The sample comprised adult members of the general public in
England and Wales, who were members of a panel of a market
research agency, ResearchNow. A ‘minimum quota’ approach,
combined with a targeted invitation strategy, was used to ensure
that the sample was representative of the general population in
terms of key observable characteristics. Individuals who had
recently completed health-related surveys were not invited to take
part. The average panel member completes six surveys per year.
Respondents were compensated by way of ‘reward points’ which
can be redeemed for gift vouchers or charity donations.
Web-based surveys offer a quick and cost-effective means of
collecting a large amount of choice data, and can be custom-
designed to present and elicit information in a clear, user-friendly
manner. Interviewer-led survey administration is often preferred
because the interviewer can explain the instructions more fully if
required (Bridges et al., 2011) and respondents may be more
attentive whilst under supervision. However, the use of in-
terviewers can lead to forms of interviewer bias, which is not the
case with web-based surveys.
Whilst the vast majority of households in the UK now have
access to the Internet (Ofﬁce for National Statistics, 2001), there
remain concerns about the extent towhich a sample of online panelmembers can be said to be representative of the general popula-
tion. Although quotas can be used to ensure representativeness in
terms of certain observable characteristics (e.g. age), it is likely that
the sample will still be systematically different in terms of other
unobservable characteristics. However, this issue is not speciﬁc to
web-based data collection. The types of individuals who are willing
to allow interviewers into their homes for face-to-face interviews,
for example, are similarly unlikely to be representative of the
general population.
The survey and sample recruitment procedures were given
ethics approval by the Ethics Committee of the University of Shef-
ﬁeld's School of Health and Related Research. The ethics approval
required us to destroy any information provided by respondents
who did not complete the survey in full.
2.6. Piloting
The main study was preceded by a pilot, which used a conve-
nience sample of 12 members of non-academic staff and post-
graduate research students at the University of Shefﬁeld. Face-to-
face interviews were conducted by one of the authors (KKS) in
which respondents completed the survey without assistance, and
then answered verbal probing questions for feedback about the
survey and approach.
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ability of the proposed methods. All of the respondents stated that
they were able to understand and complete the questions without
assistance.Table 2
Sample background characteristics.
# % Gen popn%
Total 3969 100 100
Gender
Male 1942 49 49
Female 2027 51 51
Age
18e24 404 10 11
25e44 1413 36 38
45e64 1228 31 31
65þ 924 23 21
Social gradea
A 221 6 4
B 1114 28 22
C1 1150 29 27
C2 645 16 22
DE 357 9 16
E 482 12 8
Household composition
With children 963 24
Without children 3006 76
Education
None beyond minimum school leaving age 889 22
Beyond minimum school leaving age; no degree 1244 31
Beyond minimum school leaving age; degree 1836 46
Self-reported general health level
Very good 1008 25
Good 1958 49
Fair 770 19
Poor 210 5
Very poor 23 1
Experience of close friends or family with terminal illness
Yes 2689 68
No 1197 30
Question skipped by respondent 83 2
a Refers to the occupation/qualiﬁcations/responsibilities of the chief wage earner
of the respondent's household; see National Readership Survey (2012e3).2.7. Data analysis
Choice dataweremodelled using a random utility maximisation
framework (Louviere et al., 2000) using STATA 11.2 software. As the
data were binary choice data e ‘1’ representing one option being
chosen and ‘0’ representing the other being chosen e conditional
logit regressions were used.
The model estimated is of the form:
V ¼ b1LE without treatment þ b2QOL without treatment
þ b3ðQOL gain*LE without treatmentÞ
þ b4ðLE gain*QOL without treatmentÞ
þ b5ðLE gain*QOL gainÞ þ b6EOL
The explanatory variables LE (life expectancy)without treatment
and QOL (quality-of-life) without treatment represent the baseline
health of the patients. The three interactions terms together make
up QALY gains (quality-of-life improvement for a given level of life
expectancy; life extension for a given level of quality-of-life; and
life extension combined with quality-of life improvement). These
variables were treated as continuous. We also included an end-of-
life dummy variable that took a value of 1 for proﬁles that would
meet the NICE criteria for deﬁning a life-extending end-of-life
treatment (i.e. life expectancy without treatment of less than or
equal to 24 months; life expectancy gain of greater than or equal to
three months) and 0 otherwise. We assessed the performance of
models both with and without the end-of-life dummy by exam-
ining the Akaike and Bayesian information criteria (Akaike, 1973;
Schwartz, 1978) and conducting likelihood ratio tests.
The coefﬁcients estimated in the model can be summed to give
the overall utility for each proﬁle (combination of attribute levels).
This gives us an indication of the relative social value of the 110
proﬁles in the experimental design.
As described above, the probability of choosing a given proﬁle
from the complete set of proﬁles can be predicted from the model
estimates. Following the approach used by Green and Gerard
(2009) we calculated the relative predicted probabilities for all of
the 110 proﬁles, allowing us to compare the proﬁles with higher
probabilities (those which are likely to be most preferred overall)
with those with lower probabilities (those which are likely to be
least preferred overall). This approach allows us to identify not only
which attributes have statistically signiﬁcant coefﬁcients, but also
which attributes are meaningful drivers of respondents' choices.
Finally, we deﬁned a priori a selection of respondent subgroups
whose choices may be expected to differ from those of the rest of
the sample. These were: (i) respondents with experience of close
friends or family with terminal illness; (ii) respondents with re-
sponsibility for children under 18; (iii) respondents who left a
(optional) comment in the open-ended box at the end of the survey;
and (iv) respondents who completed the questions much quicker
than average. Family circumstances and personal experience of
terminal illness were mentioned as inﬂuences on respondents'
preferences in our earlier studies (Shah et al., 2011; 2014); whether
a comment was left and how quickly the questions were completed
may be indicators of respondent engagement. For each subgroup,
we estimated the best ﬁtting model and compared the results
to those of the same model using the full sample.
Throughout our analyses we assumed a zero discount rate based
on the lack of evidence from our preliminary studies (Shah et al.,2011; 2014) that time preference is a motivating factor for giving
higher priority to end-of-life patients.3. Results
Data collection was undertaken in early 2012. In total, 43,000
individuals were invited by email to take part in the survey, of
whom 5308 clicked on the link to access the survey (response
rate ¼ 12.3%). Of the individuals who accessed the survey, 4008
completed the survey in full (completion rate ¼ 75.5%). The
remainder either did not give consent to take part, or began the
survey but dropped out without completing all of the questions.
Respondents who spent less than 3 min on the questions (n ¼ 39)
were excluded from the ﬁnal data set, leaving 3969 respondents
(39,690 pairwise observations).
Table 2 presents the background characteristics of the sample,
which was representative of the general population in England and
Wales with respect to age and gender (Ofﬁce for National Statistics,
2011), and comprised a larger proportion of individuals in the
highest and very lowest social grades (National Readership Survey,
2012-3).
Three hundred and eighty-nine respondents (9.8%) failed to
choose the dominant option when faced with choice sets in which
one alternative dominated the other (i.e. where both patients have
the same amount of life expectancy and quality-of-life without
treatment, but one patient gains more life expectancy and more
quality-of-life from treatment than the other). However, it is not
necessarily the case that these preferences are ‘irrational’e Lancsar
and Louviere (2006) warn against researchers imposing their own
preferences by deleting responses that do not conform to their
Table 3
Average level of agreement, by choice type.
Choice
type
No. choice
sets
Description Level of agreement
(% respondents who
chose patient X)
2 11 Both patients have the same
LE/QOL without treatment.
Patient X gains more LE and
more QOL from treatment than
patient Y.
92%
13 5 Patient X has shorter LE and
higher QOL without treatment
and gains more LE from
treatment than patient Y.
85%
6 1 Patient X has lower QOL
without treatment and gains
more LE and more QOL from
treatment than patient Y.
85%
1 14 Patient X has longer LE without
treatment and gains more QOL
from treatment than patient Y.
78%
12 2 Patient X has shorter LEwithout
treatment and gains more LE
from treatment than patient Y.
76%
9 4 Patient X has longer LE without
treatment and gains more LE
from treatment than patient Y.
74%
11 2 Patient X has longer LE and
lower QOL without treatment
and gains more QOL from
treatment than patient Y.
72%
8 4 Patient X has shorter LEwithout
treatment and higher QOL
without treatment than patient
Y. Both patients gain same
amount of LE/QOL from
treatment.
68%
7 5 Patient X has shorter LE and
lower QOL without treatment
and gains more QOL from
treatment than patient Y.
68%
10 3 Patient X has longer LE and
higher QOL without treatment
than patient Y. Both patients
gain same amount of LE/QOL
from treatment.
66%
3 10 Patient X has shorter LEwithout
treatment and gains more QOL
from treatment than patient Y.
62%
4 10 Both patients have the same LE/
QOL without treatment. Patient
X gains more QOL from
treatment; patient Y gains more
LE from treatment.
59%
5 9 Patient X has lower QOL
without treatment and gains
more QOL and less LE from
treatment than patient Y.
58%
Table 4
Conditional logit modelling results.
Attribute Model without end-of-life dum
Coefﬁcient Std. erro
LE without treatment 0.10715 0.00696
QOL without treatment 0.06357 0.04877
Interaction: QOL gain# LE without treatment 0.81567 0.01652
Interaction: LE gain# QOL without treatment 2.71342 0.05990
Interaction: LE gain# QOL gain 3.17557 0.10330
End-of-life dummy N/A N/A
a Akaike information criterion ¼ 43,577; Bayesian information criterion ¼ 43,623.
b Akaike information criterion ¼ 43,358; Bayesian information criterion ¼ 43,414.
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the analysis.
3.1. Descriptive statistics of the choices made
For each choice set, we calculated the ‘level of agreement’
amongst respondents in terms of the proportion choosing the
majority choice. Table 3 reports the average level of agreement for
the choice sets belonging to each ‘choice type’. The majority of
respondents chose to treat the patient who gains more from
treatment, regardless of whether that patient is better or worse off
without treatment. Across the three choice sets in which the gains
from treatment are the same for both patients and one patient is
worse off without treatment in terms of both life expectancy and
quality-of-life, the better-off patient was chosen 66% percent of the
time.
Overall, there was a statistically signiﬁcant tendency (p < 0.01)
to choose to treat the alternative labelled patient B (the alternative
appearing at the bottom of the respondent's screen).
3.2. Discrete choice model results
Table 4 reports the results of the conditional logit modelling.
Note that the parameters have been coded such that that 1 year in
full health is given a value of 1. We estimated two models e one
with and one without the end-of-life dummy variable described in
Section 2.7. The model with the end-of-life dummy performed
better according to the Akaike and Bayesian information criteria
and likelihood ratio tests (p < 0.01).
In both models, the coefﬁcient for life expectancy without
treatment is negative and statistically signiﬁcant, which indicates
that respondents are more likely to choose to treat the patient with
shorter life expectancy without treatment, ceteris paribus. The co-
efﬁcient for quality-of-life without treatment is not statistically
signiﬁcant in either model. The coefﬁcients for the three in-
teractions that make up QALY gains are all positive and statistically
signiﬁcant, and considerably larger in magnitude than the coefﬁ-
cient for life expectancy without treatment. The coefﬁcient for the
interaction between life expectancy gain and quality-of-life
without treatment is substantially larger than the coefﬁcient for
the interaction between quality-of-life gain and life expectancy
without treatment. This indicates that respondents' choices are
driven by life extensions to a greater degree than by quality-of-life
improvements. The coefﬁcient for the end-of-life dummy is posi-
tive and statistically signiﬁcant, which indicates that respondents
are more likely to choose a treatment that meets the NICE criteria
than one that does not.
To assist interpretation of themodel results, Table 5 presents the
utility scores based on the best ﬁtting model for a selection of the
proﬁles, as well as the predicted probability of choosing each proﬁle
from the full set of 110 proﬁles.mya Best ﬁtting model (with end-of-life dummy)b
r p-value Coefﬁcient Std. error p-value
0.00 0.06945 0.00736 0.00
0.19 0.00051 0.04936 0.99
0.00 0.84535 0.01682 0.00
0.00 2.39408 0.06305 0.00
0.00 2.76204 0.10616 0.00
N/A 0.37253 0.02510 0.00
Table 5
Estimated utility score and predicted probability of choice for the highest and lowest ranked proﬁles.
Rank LE without
treatment
(mths)
QOL without
treatment (%)
LE gain (mths) QOL gain (%) QALYs without
treatment
QALYs gained
from treatment
Utility Prob. Cumul. Prob.
1 60 50 12 50 2.500 3.500 4.3445 0.1351 0.1351
2 36 50 12 50 1.500 2.500 3.6380 0.0667 0.2018
3 12 50 12 50 0.500 1.500 3.3041 0.0477 0.2495
4 24 50 12 50 1.000 2.000 3.2848 0.0468 0.2964
5 60 50 6 50 2.500 3.000 3.0554 0.0372 0.3336
6 3 50 12 50 0.125 1.125 3.0392 0.0366 0.3702
7 3 100 12 0 0.250 1.000 2.7498 0.0274 0.3976
8 12 100 12 0 1.000 1.000 2.6977 0.0260 0.4237
9 60 50 12 25 2.500 2.000 2.5973 0.0235 0.4472
10 60 50 3 50 2.500 2.750 2.4109 0.0195 0.4668
11 12 50 12 25 0.500 1.000 2.4022 0.0194 0.4861
12 36 50 6 50 1.500 2.000 2.3490 0.0184 0.5045
13 36 50 12 25 1.500 1.500 2.3135 0.0177 0.5222
14 3 50 12 25 0.125 0.813 2.2958 0.0174 0.5396
15 24 100 12 0 2.000 1.000 2.2557 0.0167 0.5564
16 60 50 2 50 2.500 2.667 2.1961 0.0158 0.5721
17 36 100 12 0 3.000 1.000 2.1862 0.0156 0.5878
18 24 50 12 25 1.000 1.250 2.1716 0.0154 0.6031
19 60 100 12 0 5.000 1.000 2.0474 0.0136 0.6167
20 12 50 6 50 0.500 1.000 2.0150 0.0132 0.6299
e e e e e e e e e e
10 most preferred proﬁles 2.750 0.600 0.875 0.375 1.438 2.038 3.1121 0.04668
20 most preferred proﬁles 2.638 0.625 0.846 0.313 1.600 1.680 2.6677 0.03149
55 most preferred proﬁles 2.268 0.600 0.558 0.277 1.305 1.201 1.7856 0.01570
55 least preferred proﬁles 2.232 0.627 0.170 0.132 1.457 0.310 0.3081 0.00249
20 least preferred proﬁles 2.488 0.625 0.117 0.050 1.644 0.093 0.0156 0.00179
10 least preferred proﬁles 3.225 0.600 0.108 0.025 2.013 0.069 0.0687 0.00164
e e e e e e e e e e
91 24 50 3 0 1.000 0.125 0.1606 0.0021 0.9662
92 12 50 0 25 0.500 0.250 0.1421 0.0020 0.9683
93 12 100 1 0 1.000 0.083 0.1306 0.0020 0.9703
94 12 50 2 0 0.500 0.083 0.1303 0.0020 0.9723
95 36 50 3 0 1.500 0.125 0.0912 0.0019 0.9742
96 3 50 0 50 0.125 0.125 0.0886 0.0019 0.9761
97 3 50 1 0 0.125 0.042 0.0826 0.0019 0.9780
98 24 100 1 0 2.000 0.083 0.0611 0.0019 0.9799
99 24 50 2 0 1.000 0.083 0.0609 0.0019 0.9817
100 60 100 2 0 5.000 0.167 0.0523 0.0018 0.9836
101 3 50 0 25 0.125 0.063 0.0357 0.0018 0.9854
102 12 50 1 0 0.500 0.042 0.0306 0.0018 0.9872
103 36 100 1 0 3.000 0.083 0.0083 0.0017 0.9889
104 36 50 2 0 1.500 0.083 0.0086 0.0017 0.9907
105 24 50 1 0 1.000 0.042 0.0389 0.0017 0.9924
106 60 50 3 0 2.500 0.125 0.0477 0.0017 0.9940
107 36 50 1 0 1.500 0.042 0.1083 0.0016 0.9956
108 60 100 1 0 5.000 0.083 0.1472 0.0015 0.9971
109 60 50 2 0 2.500 0.083 0.1475 0.0015 0.9986
110 60 50 1 0 2.500 0.042 0.2472 0.0014 1.0000
Note: all outcomes are undiscounted.
Fig. 2. Levels of QALYs without treatment/gained from treatment associated with all
K.K. Shah et al. / Social Science & Medicine 124 (2015) 48e5654The highest ranked proﬁles all involve substantial treatment
gains. All of the proﬁles ranked between 1st and 25th involve a life
expectancy gain of 12months and/or a quality-of-life gain of 50%. In
contrast, the lowest ranked proﬁles mostly involve a small life ex-
pectancy gain and no quality-of-life gain. A similar pattern with
respect to life expectancy without treatment does not exist e
proﬁles involving the highest and lowest levels for this attribute (60
months and three months, respectively) appear at both the top and
bottom of Table 5. Quality-of-life without treatment is 50% in most
of the highest ranked proﬁles, but this is always accompanied by a
non-zero quality-of-life gain from treatment. There is little differ-
ence between the highest and lowest ranked proﬁles in terms of
QALYs without treatment e the key driver is the difference in the
sizes of the QALY gains from treatment.
Fig. 2 illustrates the levels of QALYs without treatment and
QALYs gained from treatment associated with all of the 110 proﬁles,
where the horizontal axis represents the standardised predicted110 proﬁles.
K.K. Shah et al. / Social Science & Medicine 124 (2015) 48e56 55probabilities from the lowest (least preferred) to the highest (most
preferred) proﬁle. Whilst the patterns are noisy, the green linear
trendline for QALYs gained from treatment has a clear upward
slope (the larger the size of the QALY gains, the greater the prob-
ability of the proﬁle being chosen). The blue linear trendline for
QALYs without treatment is relatively ﬂat, indicating that the
number of QALYs without treatment does not have a major effect
on the probability of the proﬁle being chosen.3.3. Subgroup analysis
As described in Section 2.7, we deﬁned four respondent sub-
groups according to their responses to the background questions or
to the ways in which they completed the survey. We estimated the
best ﬁtting model for each subgroup and compared the results to
those of the same model using the full sample. This analysis indi-
cated no difference in the signs or approximate magnitude of the
coefﬁcients for any of the subgroups compared with the entire
sample (except for the coefﬁcient for quality-of-life without treat-
ment, which was not robust across models and never found to be
statistically signiﬁcant). We also re-ran the best ﬁtting model
excluding the 389 respondents who failed to select the dominant
alternative when faced with choice sets in which one alternative
dominated the other. Excluding these respondents did not change
our conclusions from the regression results.4. Discussion
This study used aweb-based survey to elicit the preferences of a
large general public sample in England andWales, representative in
terms of age and gender, over a range of health care priority setting
scenarios, focussing on social preferences regarding the prioritisa-
tion of treatments for patients with short life expectancy. The study
used NICE's supplementary policy for the appraisal of life-
extending end-of-life treatments as an example to explore issues
that have potential relevance in other jurisdictions in which deci-
sion makers are considering whether health gains should be
weighted differently for different groups of patients.
The results show that choices about which patient to treat are
inﬂuencedmore by the sizes of the gains achievable from treatment
than by patients' life expectancy or quality-of-life in absence of
treatment. There is certainly no indication that being at the end-of-
life is the driving factor; in fact, the average level of life expectancy
without treatment in the 55 proﬁles most likely to be chosen is
almost identical to that in the 55 proﬁles that are least likely to be
chosen.
In line with the ﬁndings of our earlier work (Shah et al., 2011;
2014), the results show that people's preferences are heteroge-
neous. Although the conditional logit model is unable to account
for the panel nature of the data, our analysis of choice frequencies
at the individual respondent level showed that some respondents
appear to support a QALY-maximisation type objective throughout;
a small minority always seek to treat those who are worse off
without treatment; but the majority seem to advocate a mixture of
the two approaches. These heterogeneous preferences do not
appear to be well predicted by respondents' observable
characteristics.
The main ﬁndings of this study do not necessarily refute evi-
dence elsewhere in the literature of popular support for the use of
severity as a priority setting criterion (Shah, 2009). Our study
focused on a small range of scenarios, all of which involve relatively
poor prognoses (in terms of life expectancy). Across all of the
proﬁles included in the design, the patient who is ‘best off’ without
treatment would still die within ﬁve years.The outcomes examined in this study were not adjusted to ac-
count for any possible social time preference. Applying a positive
discount rate would likely further strengthen the ﬁnding that re-
spondents do not place special value on treating patients with short
life expectancy, though we would expect the effect of discounting
to be quite small given the relatively short timeframes included in
the study design.
The web-based survey provided an efﬁcient means of obtaining
a large sample. The response rate observed is not unusual for a non-
probability-based panel sample, and cannot easily be compared
with response rates from studies using different modes of admin-
istration (for example, because many of the individuals invited to
take part may not be active members of the panel) (Baker et al.,
2010b). However, this mode of administration offers limited op-
portunity for debrieﬁngwith respondents about their experience of
completing the survey (although our earlier studies and piloting
were useful in this respect). The study was designed in such a way
that the ranking of the proﬁles would not be expected to differ if
some respondents failed to pay adequate attention to the choice
tasks (e.g. making choices at random). Nevertheless, if respondents
had failed to understand the instructions, then this could be
problematic. For example, they may mistakenly believe that the
tasks require them to choose which patient they would prefer to be
in the position of, rather than which patient they would prefer the
health service to treat. A useful addition to future stated preference
studies, particularly those administered in an unsupervised setting,
would be to design follow-up questions which can be used to check
whether respondents agree with the policy implications of their
responses to the questions. A high level of agreement would add
legitimacy to the results.
The ﬁnding that respondents weremore likely to choose to treat
the alternative appearing at the bottom of the screen is consistent
with ﬁndings reported elsewhere in the literature of bias due to the
positioning of choice options (Spalek and Hammad, 2005).
NICE's current criteria for determining whether a treatment
should be a candidate for special consideration are that it is indi-
cated for patients with less than 24 months of life expectancy and
that it extends life by at least three months. Hence, a treatment
offering 0.5 QALYs through a 12month life expectancy gain (and no
quality-of-life gain) to patients with 24 months life expectancy at
50% quality-of-life without treatment would meet these criteria. An
alternative treatment, also offering 0.5 QALYs through a 25%
quality-of-life gain (and no life expectancy gain) to the same pa-
tients would not meet the criteria for being eligible for special
consideration. The results of this study indicate that the proﬁle
representing the former treatment would be more likely to be
chosen (ranked 44th with a 0.51% probability of being chosen) than
the proﬁle representing the latter treatment (ranked 83rd; 0.23%).
This suggests that the focus on life extensions and absence of
quality-of-life improvements in the criteria may be consistent with
public preferences, although some of the descriptive statistics
analysis (Table 3) suggests otherwise.
An examination of the impact of marginal changes in any of the
attribute levels from the proﬁle representing a treatment that just
meets the current NICE end-of-life criteria suggests that amending
the life expectancy without treatment criterion would not have a
major effect on utility. The predicted probability of choosing a
proﬁle involving a life expectancy gain of three months is much the
same regardless of whether the patient's life expectancy without
treatment is three, 24 or 36 months. By comparison, a proﬁle
involving a life expectancy gain of six months is considerably more
likely to be chosen than an otherwise identical proﬁle involving a
life expectancy gain of three months. We also tested an alternative
model in which the end-of-life dummy was deﬁned in terms of life
expectancy without treatment but not life expectancy gain. The
K.K. Shah et al. / Social Science & Medicine 124 (2015) 48e5656coefﬁcient for this end-of-life dummy was small and not statisti-
cally signiﬁcant. This suggests that any observed support for the
NICE policy amongst this sample requires that the policy includes a
life extension criterion.
Overall, this study provides only limited evidence to suggest
that members of the general public prefer to give higher priority to
life-extending end-of-life treatments than to other types of treat-
ment. When asked to make decisions about the treatment of hy-
pothetical patients with relatively short life expectancies, most
people's choices are driven by the size of the gains offered by
treatment.
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